EBIO Eleven Biotherapeutics Inc.

1.60
-0.02  -1%
Previous Close 1.62
Open 1.70
Price To book 1.52
Market Cap 39521194
Shares 24,700,746
Volume 289,575
Short Ratio 7.34
Av. Daily Volume 301,149

SEC filingsSee all SEC filings

  1. 8-K - Current report 171098076
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171030326
  3. 8-K - Current report 171026884
  4. 8-K - Current report 17904612
  5. 8-K - Current report 17861137

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2a planned.
Proxinium
Squamous cell carcinoma of the head and neck - cancer
Phase 3 enrollment to be completed 1Q 2018, with 3-month top-line data due mid-2018 and 12-month data due 2Q 2019.
Vicinium
Non-muscle invasive bladder cancer (NMIBC)
Phase 3 topline data showed endpoints not met mid May 2015
Isunakinra (EBI-005)
Moderate to severe dry eye disease

Latest News

  1. Eleven Biotherapeutics Announces Completion of Vicinium Manufacturing for Ongoing Clinical Trials in Non-Muscle Invasive Bladder Cancer
  2. Eleven Biotherapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
  3. Edited Transcript of EBIO earnings conference call or presentation 14-Aug-17 12:00pm GMT
  4. Eleven Biotherapeutics Reports Second Quarter 2017 Financial Results
  5. Investor Network: Eleven Biotherapeutics, Inc. to Host Earnings Call
  6. Eleven Biotherapeutics to Report Second Quarter 2017 Financial Results on Monday, August 14, 2017
  7. Eleven Biotherapeutics to Present at Canaccord Genuity 37th Annual Growth Conference
  8. ETFs with exposure to Eleven Biotherapeutics, Inc. : July 13, 2017
  9. Eleven Biotherapeutics to Present at 2017 Marcum MicroCap Conference
  10. Eleven Biotherapeutics to Collaborate with AstraZeneca and the National Cancer Institute on Development of ViciniumTM in Combination with Durvalumab for the Treatment of Non-Muscle Invasive Bladder Cancer
  11. Eleven Biotherapeutics Announces Data and Safety Monitoring Board (DSMB) Recommendation to Continue Phase 3 Registration Trial with Vicinium™ in Non-Muscle Invasive Bladder Cancer Based on Review of Safety and Efficacy Data
  12. ETFs with exposure to Eleven Biotherapeutics, Inc. : May 26, 2017
  13. Eleven Biotherapeutics, Inc.: Fading performance but may be making a comeback?
  14. Eleven Biotherapeutics Continues Expansion of Clinical Development Team with Appointment of David Brooks, M.D., Ph.D., to Senior Vice President, Clinical Development
  15. Eleven Biotherapeutics, Inc. :EBIO-US: Earnings Analysis: Q1, 2017 By the Numbers : May 8, 2017
  16. Eleven Biotherapeutics Reports First Quarter 2017 Financial Results
  17. Eleven Biotherapeutics to Report First Quarter 2017 Financial Results on Thursday, May 4, 2017

SEC Filings

  1. 8-K - Current report 171098076
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171030326
  3. 8-K - Current report 171026884
  4. 8-K - Current report 17904612
  5. 8-K - Current report 17861137
  6. S-8 - Securities to be offered to employees in employee benefit plans 17816220
  7. S-8 - Securities to be offered to employees in employee benefit plans 17816212
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 17814881
  9. 8-K - Current report 17811850
  10. 8-K - Current report 17802044